A study out this week suggests that semaglutide—the active ingredient in popular obesity drug Wegovy—might be able to help people struggling with alcohol use disorder, too. In a small sample of cases, researchers found evidence that people who took semaglutide for weight loss also experienced a significant reduction…
There’s officially a new and fierce competitor for Novo Nordisk’s Wegovy (semaglutide) when it comes to weight loss. On Wednesday, the Food and Drug Administration approved the drug tirzepatide, developed by Eli Lilly, as a treatment for obesity. The weekly injectable drug will be sold under the brand name Zepbound.
Getty Images
Health officials in Austria are the latest to warn the public to stay away from sketchy sources of semaglutide, the active ingredient in popular weight loss drugs Wegovy and Ozempic, following recent reports of severe adverse effects linked to counterfeit products. Residents have reportedly been hospitalized with…
New research suggests that Eli Lilly’s tirzepatide can boost existing efforts to lose weight. The company’s latest clinical trial found that people who dropped at least 5% of their weight before taking the drug went on to lose substantially more weight than those who took a placebo. Those in the treatment group…
Babies’ and toddlers’ access to more screen time could lead to developmental risks, according to a new study published in
Wegovy, the popular obesity treatment, also seems to offer heart health benefits. On Tuesday, Novo Nordisk reported the results of a comprehensive clinical trial evaluating the drug’s efficacy in preventing heart attacks and strokes in overweight or obese individuals. According to the company, Wegovy cut the risk of…
